Göknar N, Webb H, Waters A, et al. - Although steroid treatment for active disease is required in pediatric nephrotic syndrome cases, these patients can improve their obesity as well as overweight and also improve their linear growth from their first to last visit.

• In children, steroid treatment for a long-term can result in obesity and negative impact on growth.

• A total of 265 children who received glucocorticoids for nephrotic syndrome for a mean duration of 43 months (range: 6–167, IQR: 17, 63.3), were analyzed.

• Mean first BMI SDS and final were + 1.40 ± 1.30 and + 0.79 ± 1.30, respectively.

• Obesity (BMI ≥ 95 ^th percentile) and overweight (BMI 85 ^th –95 ^th percentile) were present in 41.4% and 19.5% of the patients at initial evaluation, and in 24% and 17% respectively at the last clinical visit.

• At last clinical visit, lower BMI SDS was evident in children, relative to initial assessment.

• In the cohort, the mean first height SDS was − 0.11 ± 1.22 and final score 0.078 ± 1.14.

• Steroid-sparing drugs were used to treat almost 85% of patients.